Inhibition of the Human Ether-a-go-go-related Gene (HERG) Potassium Channel by Cisapride: Affinity for Open and Inactivated States

Overview

Journal Br J Pharmacol

Publisher Wiley

Specialty Pharmacology

Date 1999 Oct 8

PMID 10510456

Citations 28

Authors

B D Walker

C B Singleton

J A Bursill

K R Wyse

S M Valenzuela

M R Qiu

S N Breit

T J Campbell

Affiliations

Soon will be listed here.

Abstract

1 Cisapride is a prokinetic agent which has been associated with QT prolongation, torsades de pointes and cardiac arrest. The cellular mechanism for these observations is high affinity blockade of IKr (encoded by HERG). 2 In a chronic transfection model using CHO-K1 cells, cisapride inhibited HERG tail currents after a step to +25 mV with similar potency at room and physiological temperatures (IC50 16. 4 nM at 20-22 degrees C and 23.6 nM at 37 degrees C). 3 Channel inhibition exhibited time-, voltage- and frequency-dependence. In an envelope of tails test, channel blockade increased from 27+/-8% after a 120 ms depolarizing step to 50+/-4% after a 1.0 s step. These findings suggested affinity for open and/or inactivated channel states. 4 Inactivation was significantly accelerated by cisapride in a concentration-dependent manner and there was a small (-7 mV) shift in the voltage dependence of steady state inactivation. 5 Channel blockade by cisapride was modulated by [K+]o, with a 26% reduction in the potency of channel blockade when [K+]o was increased from 1 to 10 mM. 6 In conclusion, HERG channel inhibition by cisapride exhibits features consistent with open and inactivated state binding and is sensitive to external potassium concentration. These features may have significant clinical implications with regard to the mechanism and treatment of cisapride-induced proarrhythmia.

Citing Articles

Liu Z, Wang F, Yuan H, Tian F, Yang C, Hu F BMC Biol. 2024; 22(1):29.

PMID: 38317233 PMC: 11380439. DOI: 10.1186/s12915-024-01833-0.

Systematical Evaluation of the Structure-Cardiotoxicity Relationship of 7-Azaindazole-based PI3K Inhibitors Designed by Bioisosteric Approach.

Wu T, Chen Y, Yang C, Lu M, Geng F, Guo J Cardiovasc Toxicol. 2023; 23(11-12):364-376.

PMID: 37787964 DOI: 10.1007/s12012-023-09809-2.

Inhibition of the hERG Potassium Channel by a Methanesulphonate-Free E-4031 Analogue.

Helliwell M, Zhang Y, El Harchi A, Dempsey C, Hancox J Pharmaceuticals (Basel). 2023; 16(9).

PMID: 37765012 PMC: 10536391. DOI: 10.3390/ph16091204.

GCMS fingerprints and phenolic extracts of inhibit key enzymes associated with type 2 diabetes.

Adelusi T, Boyenle I, Tolulope A, Adebisi J, Fatoki J, Ukachi C J Taibah Univ Med Sci. 2023; 18(2):337-347.

PMID: 36817213 PMC: 9926220. DOI: 10.1016/j.jtumed.2022.09.011.

Ligand-based prediction of hERG-mediated cardiotoxicity based on the integration of different machine learning techniques.

Delre P, Lavado G, Lamanna G, Saviano M, Roncaglioni A, Benfenati E Front Pharmacol. 2022; 13:951083.

PMID: 36133824 PMC: 9483173. DOI: 10.3389/fphar.2022.951083.

References

Kiehn J, Lacerda A, Wible B, Brown A . Molecular physiology and pharmacology of HERG. Single-channel currents and block by dofetilide. Circulation. 1996; 94(10):2572-9. DOI: 10.1161/01.cir.94.10.2572. View

Suessbrich H, Waldegger S, Lang F, Busch A . Blockade of HERG channels expressed in Xenopus oocytes by the histamine receptor antagonists terfenadine and astemizole. FEBS Lett. 1996; 385(1-2):77-80. DOI: 10.1016/0014-5793(96)00355-9. View

Spector P, Curran M, Zou A, Keating M, Sanguinetti M . Fast inactivation causes rectification of the IKr channel. J Gen Physiol. 1996; 107(5):611-9. PMC: 2217012. DOI: 10.1085/jgp.107.5.611. View

Wysowski D, BACSANYI J . Cisapride and fatal arrhythmia. N Engl J Med. 1996; 335(4):290-1. DOI: 10.1056/NEJM199607253350416. View

Snyders D, Chaudhary A . High affinity open channel block by dofetilide of HERG expressed in a human cell line. Mol Pharmacol. 1996; 49(6):949-55. View

Wiseman L, Faulds D . Cisapride. An updated review of its pharmacology and therapeutic efficacy as a prokinetic agent in gastrointestinal motility disorders. Drugs. 1994; 47(1):116-52. DOI: 10.2165/00003495-199447010-00008. View

Bran S, Murray W, Hirsch I, Palmer J . Long QT syndrome during high-dose cisapride. Arch Intern Med. 1995; 155(7):765-8. View

West , Martin , Bursill , Wyse , Campbell . Modulation of the Electrophysiologic Actions of E-4031 and Dofetilide by Hyperkalemia and Acidosis in Rabbit Ventricular Myocytes. J Cardiovasc Pharmacol Ther. 1997; 2(3):205-212. DOI: 10.1177/107424849700200307. View

Puisieux F, Adamantidis M, Dumotier B, Dupuis B . Cisapride-induced prolongation of cardiac action potential and early afterdepolarizations in rabbit Purkinje fibres. Br J Pharmacol. 1996; 117(7):1377-9. PMC: 1909459. DOI: 10.1111/j.1476-5381.1996.tb15295.x. View

10.

Mohammad S, Zhou Z, Gong Q, January C . Blockage of the HERG human cardiac K+ channel by the gastrointestinal prokinetic agent cisapride. Am J Physiol. 1997; 273(5):H2534-8. DOI: 10.1152/ajpheart.1997.273.5.H2534. View

11.

Barry P . JPCalc, a software package for calculating liquid junction potential corrections in patch-clamp, intracellular, epithelial and bilayer measurements and for correcting junction potential measurements. J Neurosci Methods. 1994; 51(1):107-16. DOI: 10.1016/0165-0270(94)90031-0. View

12.

Carlsson L, Amos G, Andersson B, DREWS L, Duker G, Wadstedt G . Electrophysiological characterization of the prokinetic agents cisapride and mosapride in vivo and in vitro: implications for proarrhythmic potential?. J Pharmacol Exp Ther. 1997; 282(1):220-7. View

13.

Sanguinetti M, Jurkiewicz N . Two components of cardiac delayed rectifier K+ current. Differential sensitivity to block by class III antiarrhythmic agents. J Gen Physiol. 1990; 96(1):195-215. PMC: 2228985. DOI: 10.1085/jgp.96.1.195. View

14.

Carmeliet E, Mubagwa K . Antiarrhythmic drugs and cardiac ion channels: mechanisms of action. Prog Biophys Mol Biol. 1998; 70(1):1-72. DOI: 10.1016/s0079-6107(98)00002-9. View

15.

Drolet B, Khalifa M, Daleau P, Hamelin B, Turgeon J . Block of the rapid component of the delayed rectifier potassium current by the prokinetic agent cisapride underlies drug-related lengthening of the QT interval. Circulation. 1998; 97(2):204-10. DOI: 10.1161/01.cir.97.2.204. View

16.

Sanguinetti M, Jiang C, Curran M, Keating M . A mechanistic link between an inherited and an acquired cardiac arrhythmia: HERG encodes the IKr potassium channel. Cell. 1995; 81(2):299-307. DOI: 10.1016/0092-8674(95)90340-2. View

17.

Choy A, Lang C, Chomsky D, Rayos G, Wilson J, Roden D . Normalization of acquired QT prolongation in humans by intravenous potassium. Circulation. 1997; 96(7):2149-54. DOI: 10.1161/01.cir.96.7.2149. View

18.

Suessbrich H, Schonherr R, Heinemann S, Attali B, Lang F, Busch A . The inhibitory effect of the antipsychotic drug haloperidol on HERG potassium channels expressed in Xenopus oocytes. Br J Pharmacol. 1997; 120(5):968-74. PMC: 1564549. DOI: 10.1038/sj.bjp.0700989. View

19.

Morgan Jr T, Sullivan M . An overview of class III electrophysiological agents: a new generation of antiarrhythmic therapy. Prog Med Chem. 1992; 29:65-108. DOI: 10.1016/s0079-6468(08)70005-5. View

20.

Roy M, Dumaine R, Brown A . HERG, a primary human ventricular target of the nonsedating antihistamine terfenadine. Circulation. 1996; 94(4):817-23. DOI: 10.1161/01.cir.94.4.817. View